Adding ipilimumab and nivolumab to percutaneous hepatic perfusion significantly improved progression-free survival, but with a higher rate of adverse events. The combination therapy offers a promising new treatment paradigm for patients with metastatic uveal melanoma. These results would ideally be validated in larger, multicentre randomised trials; however, conducting such studies is challenging due to the low incidence of uveal melanoma.
[Articles] Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial
The Lancet Oncology | | Linde van den Hoek, Mark Burgmans, Thaïs Tong, Jelle Goeman, Frank Speetjens, Stephanie Zunder, Arian van Erkel, Rutger van der Meer, Carla van Rijswijk, Jacob Lutjeboer, Dominique Koolhaas, Mare Jonker-Bos, Inge Roozen, Sabine Kropff, Els van Persijn van Meerten, Remco Zoethout, Elske Sitsen, Hendrik Helmerhorst, Fred Tijl, Christian Blank, Ellen Kapiteijn
Topics: skin-cancer, blood-cancer, immunotherapy, clinical-trials, research